Recent pulmonary hypertension updates: New therapies, women’s health and more

The Healio Editors have compiled a list of recent articles about pulmonary hypertension in recognition of World Pulmonary Hypertension Day.

World Pulmonary Hypertension Day aims to raise awareness of pulmonary hypertension and promote early diagnosis and access to care and treatments to increase quality of life and raise life expectancy.

See below for recent updates on the diagnosis, management and treatment of pulmonary hypertension.

Methamphetamine-associated PAH a ‘distinct clinical phenotype’

A new study highlighted the clinical differences and outcomes of methamphetamine-associated pulmonary artery hypertension compared with idiopathic PAH, including less favorable hemodynamics and regional variation. Read more

Rituximab safe, potentially effective adjuvant treatment for systemic sclerosis-PAH

B-cell depletion with rituximab is safe and may be a potentially effective treatment for patients with systemic sclerosis-associated pulmonary arterial hypertension, researchers reported. Read more

FDA approves inhaled treprostinil for pulmonary hypertension associated with ILD

The FDA approved inhaled treprostinil for the treatment of patients with pulmonary hypertension associated with interstitial lung disease, according to a press release from United Therapeutics. Read more

Sotatercept reduces pulmonary vascular resistance in patients with PAH

Treatment with sotatercept for 24 weeks resulted in a reduction in pulmonary vascular resistance among patients with pulmonary arterial hypertension therapy, according to results of the PULSAR trial. Read more

Pulmonary hypertension tied to adverse acute ischemic stroke in-hospital outcomes

Pulmonary hypertension was associated with longer hospitalization and lower odds of routine discharge among patients with acute ischemic stroke, researchers reported. Read more

Cardiopulmonary function fluctuates during menstrual cycle in premenopausal women with PAH

During the menstrual cycle, premenopausal women with pulmonary arterial hypertension experience fluctuations in markers of cardiopulmonary function that may be driven by estradiol and dehydroepiandrosterone sulfate. Read more

REVEAL Lite 2 risk calculator a simplified model to assess mortality risk in PAH

Use of an abridged version of the REVEAL 2.0 risk calculator, REVEAL Lite 2, provided a simplified method of mortality risk assessment for patients with pulmonary arterial hypertension, researchers reported in Chest. Read more

Registry highlights ‘evolving characteristics’ of patients with PAH

The U.S. Pulmonary Hypertension Scientific Registry provides novel insights on patient characteristics, diagnosis delays and treatment trends in adults with pulmonary arterial hypertension. Read more

Low-risk status achieved or maintained in minority of patients on PAH combination therapy

In a new study, initial combination therapy for pulmonary arterial hypertension improved functional class and exercise capacity after 6 months, but low-risk status was achieved or maintained in only a minority of patients. Read more